Ranbaxy Laboratories receives Civil Investigative Demand

From United States Department of Justice

Ranbaxy Laboratories announced that the Company has received a Civil Investigative Demand ("CID") from the United States Department of Justice relating to the manner in which it reports pricing data for certain products eligible for reimbursement under the Medicaid program. The CID is a request for documents and information, and is not an allegation of wrongdoing or demand for compensation. The Company would fully cooperate with this civil investigation.

Powered by Capital Market - Live News